20 May 2025- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, announces its audited results for the year ended 31 December 2024. Read more…
Significant pipeline advancements Strategic expansion into cancer immunotherapy-induced CRS unlocking a market opportunity exceeding US$10Bn Key senior management hires 30 April 2024 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces its audited results for the […]
Exclusive North American partnering deal worth up to $570m plus royalties secured for NTCD-M3 Phase 3 development plans finalised for XF-73 nasal following scientific advice from FDA and EMA XF-73 dermal commenced clinically enabling safety study sponsored by US Government’s NIAID New XF research projects initiated in cystic fibrosis and oral mucositis Leadership strengthened with appointment of […]
Significant milestones reached, well capitalised and positioned for future growth London, UK 30 March 2023 – Poolbeg Pharma Plc (AIM: POLB, OTCQB: POLBF “Poolbeg” or the “Company”) a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, is pleased to announce its audited results for the year ended 31 December 2022. Read more…
Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, is pleased to announce its audited results for the year ended 31 December 2021. Read more…
